Test Description
The C3a Complement Activation Assay is used to evaluate whether a medical device activates the complement system, a key part of the immune response. When device materials come into contact with blood, they may trigger the release of complement proteins like C3a, which can lead to inflammation or other adverse effects. This assay measures the concentration of C3a in human serum after exposure to the device, helping assess the device’s hemocompatibility and biocompatibility.
Why This Test is Performed
This test is essential for identifying whether a medical device—especially those in contact with blood—may provoke an immune response. Complement activation can lead to inflammation, thrombosis, or other complications. Testing ensures that devices meet safety standards and helps manufacturers mitigate risks before clinical use.
Have you tried our Test Navigator Tool? Try it now
Steps in Conducting This Test
- Sample Preparation: Expose the medical device material to Normal Human Serum (NHS).
- Incubation: Incubate the sample under physiological conditions to simulate real-world exposure.
- Detection: Use an ELISA kit to measure C3a levels. Absorbance is read at 450 nm using a spectrophotometer.
- Quantification: Calculate C3a concentration using a standard curve derived from known concentrations.
- Validation: If results fall outside acceptable ranges, repeat the test or reprocess the samples.
Standards, Guidance, and Regulations
- ISO 10993-4: Provides guidance on evaluating the interaction of medical devices with blood, including complement activation.
- ISO/IEC 17025:2017: Specifies general requirements for the competence of testing laboratories.
- FDA GLP (21 CFR Part 58): Ensures the quality and integrity of nonclinical laboratory studies submitted to the FDA.
| Test Code |
|---|
| V0022-000 |
